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osting by EAbstract The study was designed to develop bioadhesive patches of carvedilol hydrochloride using
chitosan (CH) and pectin (PE) interpolymer complexes and to systematically evaluate their in vitro
and in vivo performances. Mucoadhesive buccal patches of carvedilol were prepared using solvent
casting method. The physicochemical interaction between CH and PE was investigated by FTIR
and DSC studies. The patches were evaluated for their physical characteristics like mass variation,
content uniformity, folding endurance, ex vivo mucoadhesion strength, ex vivo mucoadhesion time,
surface pH, in vitro drug release, in situ release study, and in vivo bioavailability study. The swelling
index of the patches was found to be proportional to the PE concentration. The surface pH of all
the formulated bioadhesive patches was found to lie between 6.2 and 7.2. The optimized bioadhe-
sive patch (C1, CH:PE 20:80) showed bioadhesive strength of 22.10 ± 0.20 g, in vitro release of
98.73% and ex vivo mucoadhesion time of 451 min with in a period of 8 h. The optimized patch
demonstrated good in vitro and in vivo results. The buccal delivery of carvedilol in rabbits showed
a signiﬁcant improvement in bioavailability of carvedilol from patches when compared to oral
route.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.9814724622.
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lsevier1. Introduction
Mucoadhesive drug delivery systems offer beneﬁts over con-
ventional delivery methods in terms of extended residence time
of the drug at the site of application, a relatively large perme-
ability of the mucus membranes that allow rapid uptake of a
drug into the systemic circulation, and enhanced bioavailabil-
ity of therapeutic agents resulting from the avoidance of some
of the body’s natural defense mechanisms. Mucoadhesion,
deﬁned as the ability to adhere to the mucus gel layer, is a
key element in the design of these drug delivery systems (Lee
et al., 2000). Buccal mucosa is an attractive route for systemic
22 A. Kaur, G. Kaurdelivery of drugs since it is relatively permeable, with rich
blood supply (Hoogstraate et al., 1996). The problems such
as high ﬁrst-pass metabolism and drug degradation in the
harsh gastrointestinal environment can be circumvented by
administering the drug via the buccal route (Gu et al., 1988;
Lehr et al., 1992) and, buccal drug absorption can be promptly
terminated in case of toxicity by removing the dosage form
from the buccal cavity. Attempts have been made earlier to
formulate various buccoadhesive devices, including tablets
(Boyapally et al., 2010), ﬁlms (Pongjaryakui and Suksri,
2009), patches (Morrow et al., 2010), disks (Darwish et al.,
2008) and strips (Dixit and Puthil, 2009). However, buccal
ﬁlms are preferable over adhesive tablets in terms of ﬂexibility
and comfort (Gu et al., 1988). Natural polysaccharides have
been widely used as bioadhesive polymers because of their bio-
compatibility and biodegradability properties. In this study
chitosan (CH) and pectin (PE) were used as bioadhesive poly-
mers to increase the residence time of the dosage form in buc-
cal cavity. These polymers swell in aqueous media to form a
gel through which the drug has to diffuse thus; they can also
be used to control the rate of drug release.
Carvedilol is a non-selective, b-adrenergic antagonist with
no intrinsic sympathomimetic activity and is widely used to
treat essential hypertension and angina pectoris. Although it
is completely absorbed from the gastrointestinal tract, the sys-
temic availability is approximately 25–35% because of high
ﬁrst-pass metabolism. Carvedilol is metabolized primarily by
aromatic ring glucuronidation. The oxidative metabolites are
metabolized by conjugation via glucuronidation and sulfation
(Morgan, 1994). Higher bioavailability of carvedilol has been
observed following absorption from the buccal mucosa (Vami-
shi et al., 2007) and the lower parts of gastrointestinal tract
GIT (Nolte et al., 1999). This suggests that the oral availability
of carvedilol could be improved by formulating a buccoadhe-
sive dosage form. Hence, buccoadhesive patches can be envis-
aged to ensure both enhanced oral availability as well as
maintenance of effective plasma concentration over prolonged
duration by extending the release of carvedilol. This in turn is
expected to reduce the frequency of administration by main-
taining effective plasma concentration over longer duration,
providing better control of hypertension and thereby, improv-
ing patient compliance. In the present study, an attempt has
been made to develop buccal patches of carvedilol hydrochlo-
ride using CH and PE. The in vitro release characteristics of the
prepared systems were evaluated using USP type II dissolution
apparatus, the adhesion measurement was conducted using
modiﬁed balance method with porcine cheek mucosa and
in vivo study was conducted in rabbits.2. Experimental section
2.1. Materials
Carvedilol was received as a gift sample from Ranbaxy Labo-
ratories, Gurgaon, India, chitosan was a gift sample from Cen-
tral Institute of Fisheries Technology, India, Pectin was
procured from Central Drug House, India and propylene gly-
col from Fine Chemicals, India. All other reagents and chem-
icals were of analytical grade and were used as such.2.2. Methods
2.2.1. Formation of interpolymer complex between CH and PE
PE (80 mg) was dissolved in 50 ml of distilled water and CH
(20 mg) was dissolved in 50 ml of 2% (v/v) acetic acid by mag-
netic stirring for 1 h. Upon addition of PE slowly in CH solu-
tion, while stirring continuously, a solid sticky mass was
obtained. The admixture was kept at 37 C for 48 h. The
supernatant was decanted and the remaining solid complex
was dried at 50 C. The dried polymer complex of CH–PE
was sieved ﬁrst through sieve #22 and then through sieve
#80. The powdered polymer complex of CH–PE was charac-
terized using Fourier transform infrared spectroscopy (FTIR)
and differential scanning calorimetric (DSC) studies.
2.2.2. Preparation of mucoadhesive buccal patches
Buccoadhesive patches were prepared by solvent casting meth-
od. CH and carvedilol were dissolved in 2% (v/v) glacial acetic
acid solution containing ammonium acetate (5 M) and PE was
dissolved in distilled water. CH solution was then added to PE
solution with stirring. PG, 15% (v/v) was added as a plasti-
cizer. The resulting viscous solution was poured in petri plates
and dried in an oven at 50 C for 48 h. The dried ﬁlms were cut
into square pieces of sides 1.5 cm containing 6–6.5 mg of drug
per patch. The patches were packed in an aluminum foil and
stored in an airtight glass container to maintain the integrity
and elasticity of the patches. Table 1 shows the composition
of formulated buccal patches.
2.2.3. Mass uniformity and folding endurance test
Mass uniformity of the patches was tested in 10 different ran-
domly selected patches from each batch and the patch thick-
ness was measured at ﬁve different randomly selected spots
using a vernier caliper. Folding endurance of the patches was
determined by repeatedly folding one patch at the same place
till it broke or folded up to 200 times without breaking (Khur-
ana et al., 2000).
2.2.4. Drug content uniformity
Drug content uniformity was determined by dissolving the
patch by homogenization in 100 ml of an isotonic phosphate
buffer (pH 6.6) for 2 h with occasional shaking. Aliquot
(5 ml) was withdrawn and diluted with isotonic phosphate buf-
fer pH 6.6 up to 20 ml, and the resulting solution was ﬁltered
through a 0.45 mm Whatman ﬁlter paper. The drug content
was then determined spectroﬂuorometerically (Patel et al.,
2007).
2.2.5. Surface pH determination
The surface pH of the patch was determined by the method
similar to that used by Bottenberg et al. (1991). The patches
were allowed to swell by keeping them in contact with 1 ml
of distilled water for 2 h at room temperature, and pH was
noted down by bringing the electrode in contact with the sur-
face of the patch, allowing it to equilibrate for 1 min.
2.2.6. Measurement of bioadhesive strength
The bioadhesive strength of the bioadhesive patches was eval-
uated using the method reported by Gupta et al. (1992). Por-
cine cheek pouch (thickness 0.05 ± 0.01 mm) was used as
Table 1 Physical characteristics of bioadhesive carvedilol patches.
Patch code CH:PE Mass (mg) Thickness (mm) Drug content (%) Folding endurance Surface pH
A 100:0 49 ± 1 0.52 ± 0.11 97.84 ± 0.12 153 ± 13 3.3 ± 0.10
B 0:100 52 ± 1 0.66 ± 0.23 98.45 ± 0.23 175 ± 20 3.5 ± 0.11
C1 20:80 55 ± 0 0.58 ± 0.85 98.66 ± 0.15 205 ± 17 6.7 ± 0.30
C2 25:75 44 ± 1 0.45 ± 0.45 99.21 ± 0.45 179 ± 12 6.8 ± 0.15
C3 33:67 52 ± 1 0.52 ± 0.52 99.36 ± 0.650 188 ± 22 6.8 ± 0.17
C4 50:50 55 ± 1 0.69 ± 0.33 98.75 ± 1.12 186 ± 11 6.9 ± 0.16
C5 67:33 54 ± 0 0.78 ± 0.65 100.21 ± 0.63 198 ± 14 6.7 ± 0.30
C6 75:25 45 ± 1 0.65 ± 0.23 97.52 ± 0.98 201 ± 17 6.2 ± 0.15
C7 80:20 47 ± 1 0.57 ± 0.17 100.85 ± 0.85 152 ± 24 7.2 ± 0.15
All the experiments were carried out in triplicate.
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strength. The mucosal membrane was excised by removing
the underlying connective tissue. The surface of the mucosal
membrane was ﬁrst blotted with ﬁlter paper and then moist-
ened with 25 ll of buffer solution pH 6.6. The weight required
to detach the ﬁlm from the mucosal surface was determined
and force of adhesion was taken as a measure of bioadhesive
strength.
2.2.7. In vitro swelling studies of buccoadhesive patches
The degree of swelling of bioadhesive polymer is an important
factor affecting adhesion. The swelling rate of buccoadhesive
patch was evaluated by placing the ﬁlms in phosphate buffer
solution pH 6.6 at 37 ± 1 C. Six patches of each batch were
cut and weighed, and the average weight was calculated
(W1). The patches were placed in phosphate buffer and were
removed at time intervals of 0.5, 1, 2, 3, 4, 5, 6 and 7 h, excess
water on the surface was carefully absorbed using ﬁlter paper,
and swollen patches were reweighed. The average weight W2
was calculated, and the swelling index was calculated by the
formula:
Swelling index ¼W2 W1
W1
All the experiments were carried out in triplicate.
2.2.8. In vitro release studies
In vitro drug release studies were carried out employing disso-
lution test apparatus type II (USP) paddle method using
900 ml of phosphate buffer (pH 6.6) as the dissolution medium
at 50 rpm at 37 ± 0.5 C for 8 h. To provide unidirectional re-
lease, one side of each patch was attached to a glass disk with
the help of cyanoacrylate instant adhesive (Desai and Kumar,
2004). An aliquot of 5 ml was withdrawn at suitable time inter-
vals and replaced with fresh phosphate buffer (pH 6.6) main-
tained at the same temperature. Samples were then analyzed
spectroﬂuorometrically (limit of detection (LOD) was found
to be 1 ng and limit of quantitation (LOQ) was found to be
2 ng).
2.2.9. Ex vivo mucoadhesion time
This study was performed on an optimized bioadhesive patch.
The disintegration medium composed of 800 ml phosphate
buffer pH 6.6 (IPB) maintained at 37 C. A segment of porcine
check mucosa, 3 cm long, was glued to the surface of a glass
slab, vertically attached to the apparatus. The mucoadhesive
patch was hydrated from one surface using 15 ll phosphatebuffer and then the hydrated surface was brought into contact
with the mucosal membrane.
The glass slab was vertically ﬁxed to the apparatus and al-
lowed to move up and down so that the patch was completely
immersed in the buffer solution at the lowest point and was out
at the highest point. The time necessary for complete erosion
or detachment of the patch from the mucosal surface was
recorded. All the experiments were carried out in triplicate
(Nafee et al., 2004).2.2.10. In situ release studies
The studies were carried out by using Keshary–Chein glass dif-
fusion cells. Porcine cheek pouch was ﬁrst given pretreatment
by placing it between receptor and donor compartment for 3 h.
The patch was then placed in the donor compartment. The
whole assembly was maintained at 37 ± 1 C and the medium
stirred at 100 rpm. An aliquot of sample (1 ml) was taken at
suitable time intervals from the receptor compartments and
equal volume was replaced with fresh phosphate buffer
(pH 6.6) maintained at the same temperature. Samples were
analyzed spectroﬂuorometrically as for dissolution samples.2.2.11. Pharmacokinetic studies
The pharmacokinetic studies were carried out in healthy rab-
bits. The animals selected for the study had no medication
for 2 weeks prior to study. The rabbits were sedated with an
intra muscular injection of ketamine (25 mg/kg) before appli-
cation of test patch. The formulated test patch bonded directly
to a backing layer made up of ethyl cellulose was placed in the
buccal cavity. A gentle pressure was applied for 1 min and
blood samples were taken from ear vein after regular intervals
for 8 h, centrifuged at 4000 rpm for 10 min to separate plasma.
The separated plasma was stored at 4 C until analyzed. For
the quantitative determination of carvedilol in rabbit plasma,
200 ll of plasma was taken into microcentrifuge tubes fol-
lowed by addition of 100 ll of nimesulide (internal standard)
and 100 ll of 5% (w/v) trichloroacetic acid as protein precipi-
tant. The tubes were then centrifuged for 10 min at 4000 rpm.
The supernatant was separated and 1 ml of chloroform was
added and this solution was again centrifuged at 4000 rpm
for 10 min. The chloroform layer was separated and dried.
The residue was reconstituted with 1 ml of mobile phase, vor-
texed, ﬁltered and 20 ll was injected into column. Similarly,
rabbits were administered oral solution containing 6.25 mg
of carvedilol in phosphate buffer.
Figure 1 FTIR spectra of CH (A), PE (B), and interpolymer
complex ﬁlms comprising of 80:20 (C), 75:25 (D), 67:33 (E), 50:50
(F), 33:67 (G) 25:75 (H) or 20:80 (I) CH:PE ratios.
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chromatography (HPLC) method
The analysis of the plasma samples was performed using
Waters HPLC system equipped with a Waters 515 HPLC
pump, Waters 2487, Dual k Absorbance detector, and Waters
spherisorb S5 C8 column. The mobile phase comprised of a
mixture of acetonitrile and phosphate buffer pH 3.2 (60:40,
v/v). The ﬂow rate was 1 ml/min. The detection was carried
out at wavelength 242 nm (LOD was found to be 4 ng and
LOQ was found to be 5 ng). The data were acquired and pro-
cessed using Empower 2 software.
2.2.13. Statistical analysis
Analysis of variance (ANOVA) followed by Tukey’s test was
used for statistical comparison of the data. Signiﬁcance level
was ﬁxed at p< 0.05.
3. Results and discussion
In the present study, buccal patches of carvedilol were pre-
pared using different ratios of CH:PE interpolymer complexes.
3.1. Characterization of CH–PE interpolymer complex
3.1.1. FTIR analysis
The FTIR spectra of CH (Fig. 1A) showed a sharp peak of
strong intensity at 1580 cm1 which is the characteristic peak
of amino group in CH while in case of PE (Fig. 1B) sharp
peaks at 1749.9 cm1 and 1616.5 cm1 indicated the presence
of C‚O stretching of the ester and carboxyl group, respec-
tively. The FTIR spectra of CH–PE interpolymer complex
(Fig. 1C–I) indicated changes in the range of 1800–1600 cm
1, evident of interaction of amino and carboxylic groups. A
strong peak at 1627.0 and 1412.9 cm1 in C (CH:PE; 80:20),
1640.3 and 1402.7 cm1 in D (CH:PE; 75:25), 1620.5 and
1403.6 cm1 in E (CH:PE; 67:33), 1645.3 and 1417.3 cm1 in
F (CH:PE; 50:50), 1623.3 and 1403.1 cm1 in G (CH:PE;
33:67), 16.22.3 and 1404 cm1 in H (CH:PE; 25:75), 1621.0
and 1442.8 cm-1 in I (CH:PE; 20:80) indicated the presence
of –COO groups and –NHþ3 in the patches indicating inter-
polymer complexes between CH and PE (Vasilyeva et al.,
2004).
3.1.2. DSC studies
The DSC thermogram of CH or PE showed an endothermic
transition at 70 and 95 C, respectively. This could be attrib-
uted to water loss as all the powders were hydrated at 50%
RH prior to thermal analysis. Further, an exothermic transi-
tion at 311 and 242.11 C, respectively, was observed in the
DSC thermograms of CH and PE. These exothermic transi-
tions are indicative of degradation of these polymers. The
complex prepared by interacting 20:80 or 80:20 ratio of CH:PE
exhibited two endothermic transitions and an exothermic tran-
sition (Table 2). Two endothermic transitions were observed in
thermograms of CH:PE complex prepared from ratio 50:50.
However, no exothermic transition was observed in same
CH–PE ﬁlms. This might indicate that there is complete inter-
action between CH and PE. The second endothermic transi-
tion ranging from 210 to 220 C could be attributed to the
formation of carboxylate linkage between –COO of PE and
–NHþ3 of CH. Similar results have earlier been reported wherean additional endotherm at 210 C was observed when chito-
san and chondroitin sulfate interpolymer complexes were pre-
pared (Kaur et al., 2010).3.2. Physical characteristics of bioadhesive patches
The prepared patches were smooth in appearance, uniform in
thickness, mass and drug content and showed no visible
cracks. The patches were exhibiting good folding endurance
(Table 1). The thickness of the patch ranged from
0.45 ± 0.45 to 0.78 ± 0.65 mm and mass ranged from
44 ± 1 to 55 ± 1 mg. The bioadhesive patches had a surface
pH of 3.3 ± 0.10 to 7.2 ± 0.15 and the drug content in buccal
patches was found to range from 97.52 ± 0.98% to
100.85 ± 0.85%.
The surface pH of all the patches (C1–C7) was near 6 (Afra-
mian et al., 2006) and hence, these patches should not cause
any irritation in the buccal cavity.
Table 2 Thermal changes in interpolymer complexes prepared using different ratios of CH:PE.
Sample Endotherms Exotherm
First endotherm Second endotherm
Tm (C) DH (J g1) Tm (C) DH (J g1) Tm (C) DH (J g1)
CH alone 70.42 246.00 \ \ 311.32 116.46
PE alone 95.52 21.61 \ \ 242.11 43.31
CH:PE (20:80) 81.53 142.13 278.21 5.60 235.59 68.52
CH:PE (50:50) 81.04 175.50 212.34 132.62 \ \
CH:PE (80:20) 82.21 189.13 209.83 111.04 240.59 29.88
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Patch A containing CH alone showed maximum swelling.
However, patch B containing PE alone eroded after 30 min
(Fig. 1). It has been demonstrated that when a patch compris-
ing PE is placed in an aqueous medium, liquid penetrates into
the patch and a gel is formed due to uncoiling of the structure
of PE molecules and the formation of hydrogen bonds with
water molecule. As a result, the diameter of the patch increases
progressively and a distinct gel–sol boundary develops. Being
hydrophilic in nature PE after hydration and swelling, goes
into solution and erodes (Talukdar and Kinget, 1995). Due
to the hydrophilic nature of PE batch B containing PE alone
eroded within 30 min in phosphate buffer pH 6.6. The swelling
index of the CH–PE complexed ﬁlms was found to decrease as
the concentration of PE decreases in patches C1–C4. However,
an increase in the swelling index was observed in CH–PE
patches C5–C7 when the CH concentration in the patch in-
creases (Fig. 2). Ionically crosslinked ﬁlms containing CH in
cationic (protonated) forms have been reported to swell more.
The swelling is favored by the protonation and repulsion of
free ammonium groups of CH (Berger et al., 2004) thus leading
to greater swelling of these patches.
3.4. Bioadhesive strength studies
The patches formulated using CH alone (patch A) were show-
ing very less bioadhesive strength. The bioadhesive patch BFigure 2 Swelling indices (SI), bioadhesive strength (BS) and % ca
represented as mean ± SD.(PE alone) showed maximum bioadhesive strength (Fig. 2).
The force required to detach the patches from the mucosal
membrane decreased with a decrease in the PE concentration
(C1–C4). PE being hydrophilic in nature forms a gel like struc-
ture at the buccal mucosa resulting in larger surface/contact
area. The increase in the water uptake by capillary forces led
to an increased bioadhesion (Park and Munday, 2004).
However, an increase in the bioadhesive strength was ob-
served in patches C5–C7. This observation can be explained
by the presence of CH in the cationic (protonated) form in
the polymer complex. This led to electrostatic interactions be-
tween CH and negatively charged mucus (Lehr et al., 1992)
thus resulting in increased bioadhesive strength as compared
to CH alone. The formulated patches were showing statisti-
cally signiﬁcant differences (p< 0.05) in their bioadhesive
strength.
3.5. In vitro drug release studies
The patches A and B comprising CH and PE alone were either
showing too high swelling index or they were eroding, there-
fore; in vitro studies were not carried out on these patches. A
decrease in PE content in all the investigational patches (C1–
C4) resulted in slower drug release (Fig. 2). This can be attrib-
uted to the swelling and erosion behavior of PE (Sujja-arrevath
et al., 1998). The swelling and erosion of patches due to PE re-
sulted in moving boundary condition thus modifying the effec-
tive diffusivity of the drug. The continued swelling of thervedilol released from formulated bioadhesive patches. Data are
Figure 3 Plasma concentration proﬁle of carvedilol bioadhesive
patches and carvedilol aqueous solution (n= 6).
26 A. Kaur, G. Kaurpolymer matrix causes the drug to diffuse from the formula-
tion at faster rate (Agarwal and Mishra, 1999).
Further, an increase in CH concentration (patches C5–C7)
also showed an increase in drug release. This observation can
be explained due to the increased swelling of CH in these
patches leading to drug release in shorter period of time. Based
on these studies patch C1 was selected for further studies.
Patch C1 showed a residence time of 7.5 h and in situ drug
release studies showed that about 51.07% drug permeated
through porcine buccal mucosa.
3.6. In vivo evaluation of bioadhesive buccal patch of carvedilol
The mean plasma concentration of carvedilol at different time
intervals following the application of buccal patch and after
oral administration of aqueous solution of carvedilol in rabbits
is depicted in Fig. 3. The plasma concentration of carvedilol
gradually increased and attained a maximum after which aver-
age steady-state level of drug declined upto 8 h (n= 6). The
Cmax obtained after application of buccal patch was 245 ng/
ml and Tmax 4 h. The AUC total obtained after application
of buccal patch was 32.325 ng h/ml as compared to
15.05 ng h/ml obtained after the administration of carvedilol
aqueous solution. The buccal formulation (C1) selected for
in vivo study enhanced the bioavailability of carvedilol by
2.14 times with reference to an oral solution of carvedilol.
4. Conclusion
In the present investigation CH–PE interpolymer complexes
were prepared and characterized using FTIR and DSC studies.
Using these interpolymer complexes bioadhesive patches of
carvedilol hydrochloride were formulated. The bioadhesive
patches were displaying sufﬁcient bioadhesive strength and
in vitro drug release. The optimized patch C1 with interpoly-
mer complex of CH–PE in ratio of 20:80 showed an increased
bioavailability of about 2.14 times when compared to oral
route. On the basis of the above results it can be concluded
that CH–PE interpolymer complexes can be used to formulate
bioadhesive buccal patches of carvedilol hydrochloride.References
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